Patient safety and effective therapy is veryone's ultimate goal: from physicians and pharmacists to drug manufactures. That is why at Baxter Oncology we ensure our cytotoxic manufacturing process sets the global standard.

Fifty years ago we pioneered ENDOXAN (cyclophosphamide), and later HOLOXAN (ifosfamide). Since then, Baxter has beend dedicated to offering unparalleled oncology production erpertise. Our capabilities now span a wide range of outstanding oncology products, not just our original alkylating agents.

Our world-class, environmentally sustainable, dependable oncology products give patients and healthcare professionals the peace-of-mind that only comes with effective, well- tolerated therapies.

While generic drugs are considered bioequivalent to the originator's product, there can be significant differences during the manufacturing process. Baxter employs hundreds of dedicated specialists to ensure that the excellent quality of our oncology products is available to all patients in need.

What is more, our quality promies does not stop there; our dedication to vertical integration ensures we extend the integration of our synthesis and production processes to our high-tech, environment-controlled distribution process.

When you understand our unrelenting drive to be the world- leading oncology partner, it is no wonder that Baxter has invested €67 million in oncology manufacturing over the last decade.

We never accept a compromise when it is about patients' health.